

July 11, 2016
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Announcement on Achievement of a Sales Milestone for Bendamustine, an Anticancer Agent, in Taiwan, and Receipt of a Milestone Payment related thereto

SymBio Pharmaceuticals Limited (Headquarters: Tokyo; hereinafter "SymBio") announced today that the total net sales of bendamustine in Taiwan since 2012 has exceeded 2.4 million Euro according to InnoPharmax Inc. (Headquarters: Taipei; hereinafter "InnoPharmax"). InnoPharmax has exclusive development and marketing rights for bendamustine in Taiwan and sells bendamustine under the brand name of Innomustine® (Japanese brand name: TREAKISYM® Injection, which was approved in October 2010 for the indication of recurrent and refractory low-grade malignant non-Hodgkin's lymphoma and mantle cell lymphoma). Reaching this milestone has generated a milestone payment from InnoPharmax to SymBio.

In October 2011, the Taiwan Food and Drug Administration granted InnoPharmax manufacturing and marketing authorization for bendamustine for the indication of low-grade malignant non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Accordingly, InnoPharmax has been selling the product in Taiwan since February 2012. Further details of the agreement are not disclosed.

This news will have no impact on SymBio's earnings forecast for the fiscal year ending December 2016.

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125

[Glossary]

About non-Hodgkin's lymphoma

Non-Hodgkin's lymphoma is a lymphatic malignancy that does not include Hodgkin's lymphoma. In Japan, most lymphomas are non-Hodgkin's lymphoma. Non-Hodgkin's lymphoma is categorized by its progression speed, which means that lymphoma which progresses annually is low-grade and that which progresses monthly is mid to high-grade.

In December 2015, SymBio applied for the approval of the subject product for first-line treatment of low-grade malignant non-Hodgkin's lymphoma as an additional indication, which is currently under review by the Pharmaceuticals and Medical Devices Agency.

About Chronic Lymphocytic Leukemia (CLL)

CLL is a cancer of the blood characterized by the progressive accumulation of functionally incompetent lymphocytes, a type of white blood cell produced by the bone marrow and organs of the lymphatic system. The number of CLL patients in Japan is estimated to be around 2,000. In the US and EU, bendamustine has been approved for the treatment of CLL where the disease accounts for an estimated 30% of all leukemia cases. Due to the lack of effective therapies in Japan, CLL patients are seriously underserved and a high unmet medical need exists for the development of an effective alternative therapy.

In December 2015, SymBio applied for the approval of CLL as an additional indication, which is currently under review by the Pharmaceuticals and Medical Devices Agency.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March, 2005, by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the United States, called SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, USA, President: Mr. Fuminori Yoshida).

The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.